Compare Smith & Nephew plc (SNN) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs VNET Group Inc — how do they compare? Smith & Nephew plc trades at $27.17 (market cap $11.10B), while VNET Group Inc trades at $5.28 (market cap $1.47B). The key difference: Smith & Nephew plc is far larger — about 7.6× VNET Group Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and VNET Group Inc for 16 Days on average.
| SNN | VNET | |
|---|---|---|
Market Cap | $11.10B | $1.47B |
Volume | 1,051,703 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $37.17 | $14.03 |
52-Week Low | $26.42 | $5.13 |
Typical Hold Time | 120 Days | 16 Days |
Enterprise Value | $14.13B | $5.04B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
VNET trades at $5.39, near a 52-week low, with a bearish technical signal and negative earnings misses in recent quarters. The company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Positive cash flow from operations of $1.92 billion and a strategic investment closing in September 2026 provide some operational stability amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst consensus is moderately bullish with 62.5% buy ratings. Key risks include balance sheet pressures and competitive threats in the data center market, while potential upside hinges on execution of new capacity and AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
